Articles On Neuren Pharmaceuticals (ASX:NEU)

The S&P/ASX 200 Index (ASX: XJO) enjoyed a confident return to trading after the weekend this Monday. After a shaky week last week, investors seemed to come back refreshed. After an early wobble this morning, the market found its footin...

It was a pleasant end to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Friday. After yesterday's strong gain shook off the volatility that we saw earlier in the week, today's gains cemented that optimism...

The S&P/ASX 200 Index (ASX: XJO) was back to the races this Thursday, reversing yesterday's chunky loss and pushing the value of many ASX shares decisively higher. In what has turned out to be an exceptionally volatile week of trading,...

Attendees at a biotech seminar last week heard from three IPO candidates – while others are waiting in the wings Our next crop of public companies targets the big conditions including autism, multiple sclerosis and diabetes ‘Multispecific’...

S&P/ASX All Ordinaries Index (ASX: XAO) shares are down 0.26% to 8,857.9 points on Thursday. Among the 11 market sectors, financials are in the lead today, up 0.4%, as Commonwealth Bank of Australia (ASX: CBA) shares recover modes...

Highlights Healthcare slump weighed heavily on the broader market Energy and mining shares attracted renewed attention Investors tracked global inflation and oil market tensions The [ASX 200] moved lower after a sharp...

The S&P/ASX 200 Index (ASX: XJO) had a tough start to the trading week this Monday, along with many ASX shares. After ending the week on a sour note last week, investors clearly didn't regain any confidence over the weekend. The ASX 200...

The S&P/ASX 200 Index (ASX: XJO) enjoyed another strong day this Thursday, building on the stunning session we saw yesterday. By the time trading wrapped up, the ASX 200 had gained a solid 0.96%, leaving the index at 8,878.1 points. Thi...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today as the company reported Q1 2026 DAYBUE® net sales grew 20% year-on-year, reaching US$101 million. Neuren also saw its Q1 royalty income rise 23% to US$10.4 million, as...

Shares in Atlantic Lithium Ltd (ASX: A11) have jumped more than 10% after the company said it had agreed to a takeover by a Chinese company. Share price upside on the table Atlantic Lithium said in a statement to the ASX that it had...

The Cleanaway Waste Management Ltd (ASX: CWY) share price is in focus after the company reported a key Victorian Supreme Court decision relating to alleged underpayments of landfill levies at its Melbourne Regional Landfill, with a potentia...

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Thursday. In afternoon trade, the benchmark index is up 0.75% to 8,861.5 points. Four ASX shares that are rising more than most today are listed below. Here's why they are...

Shares in ASX small cap FleetPartners Group (ASX: FPR) have risen 6% at the time of writing after the company reported its half-year results, with investors encouraged by steady earnings growth, strong cash generation, and continued capital...

Alzheimer’s disease research is burgeoning – and Actinogen Medical is one of the most advanced players EBR Systems’ limited US rollout approach was a Wise move Amid increased sales, Neuren Pharmaceuticals mulls a franked dividend   No few...

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts  Dimerix moving into major catalyst window as investors look for further updates from Phase III trial of DMX-200 in FSGS Cynata has results of tw...

Highlights Healthcare sector coverage across Australian equity benchmarks spanning biotechnology, diagnostics, and medical technology Multiple healthcare entities represented across ASX 100, ASX 200, ASX 300, and All Ordinaries framewo...

ASX biotech stock Neuren Pharmaceuticals Ltd (ASX: NEU) finally delivered some good news. Shares jumped 5.7% on Wednesday to $13.00, outpacing the 2.6% gain of the S&P/ASX 200 Index (ASX: XJO). This followed the biotech company anno...

The Ides of March weighed down the sector, but green shoots of recovery may make April fools of the naysayers Telix Pharmaceuticals shares led the top end recovery with a 40% gain It’s April – and drug developers with names starting with ‘...

The step from ‘science project’ to commercial asset in the ASX-listed biotechnology landscape is defined by a handful of key milestones, and none is more important than a Phase Three interim analysis, where the most dramatic value re-rating...

Highlights Broad market recovery led by mining, technology and healthcare shares Several ASX listed companies draw attention during the rebound Energy and consumer staples sectors move in the opposite direction Austral...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a decisive relief rally this Tuesday, delivering some welcome respite for investors after yesterday's horror-show start to the week. By the time trading wrapped up today, the ASX 200 had gained a...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

ASX health sector flat for the week, while the S&P/ASX 200 falls xx% as Middle East conflict takes a toll on global markets LTR Pharma completes recruitment for a phase II pharmacokinetic clinical study of erectile dysfunction treatmen...

The Australian share market has traditionally delivered a return in the region of 10% per annum. While that is a fantastic return, it pales in comparison to the potential return on offer with the ASX 200 stock in this article. That's becaus...

Shares in Neuren Pharmaceuticals Ltd (ASX: NEU) have been under pressure in the past few months, so it's a good time to take a step back and see what the experts think about the way forward. The analyst team at Macquarie have an outperf...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

The S&P/ASX 200 Index (ASX: XJO) is having a disappointing session on Tuesday. In afternoon trade, the benchmark index is down 1.2% to 9,088.9 points. Four ASX shares that are falling more than most today are listed below. Here's why...

Highlights• Cryosite reports stronger revenue and profit across storage divisions.• Neuren addresses European regulatory setback on Rett syndrome drug.• Entropy advances psychedelic-based binge eating disorder trial. Cryosite, Vitrafy,...

ASX stalwart Cryosite and newbie Vitrafy are having their day in the sun Neuren won’t take European knock-back lying down Entropy beds down its first cohort in its groundbreaking psychedelics trial   Investors are warming to the ASX-liste...

Highlights Market momentum cools after record-breaking rally Resources and asset managers dominate early trade moves Global tensions and commodities shape market direction The ASX 200 cooled after record highs as coal...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are under pressure on Tuesday. In morning trade, the ASX 200 stock is down over 6% to $12.89. Why is this ASX 200 stock under pressure? This morning, Neuren advised that its partner, Acadia Pharm...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

It was a stunning finish to a stunning trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Friday. After a record-breaking week of new record highs, investors decided to give the share market one more before headi...

Shares in Neuren Pharmaceuticals Ltd (ASX: NEU) are slightly lower on Friday after the company released its full-year results for 2025. In early afternoon trade, the Neuren share price is down 0.37% to $13.39. Let's take a closer look...

The Alcoa Corporation CDI (ASX: AAI) share price is in focus as the company announces a quarterly dividend of US 10 cents per CDI, payable on 26 March 2026, with a record date of 10 March. What did Alcoa report? Quarterly dividend of US 10...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus after the company posted a 15% rise in 2025 DAYBUE royalties to A$65 million and a profit after tax of A$30 million. What did Neuren Pharmaceuticals report? 2025 royalty inc...

The Mesoblast Ltd (ASX: MSB) share price is focus today after the company reported a surge in revenue to US$51.3 million, thanks to the successful commercial launch of Ryoncil® in the US. What did Mesoblast report? Total revenue jumped to...

The Harvey Norman Holdings Ltd (ASX: HVN) share price is in focus today after the company posted a double digit uplift in profit before tax and raised its interim dividend for the half-year ended 31 December 2025. What did Harvey Norman rep...

The TPG Telecom Ltd (ASX: TPG) share price is in focus today after the company reported a 4.2% rise in mobile service revenue and an 18.4% jump in EBITDA for 2025, underpinned by its strongest mobile subscriber growth since 2022. What did T...

The Virgin Australia Holdings Ltd (ASX: VGN) share price is in focus after the airline reported a 11.7% lift in underlying EBIT for the first half of FY26, with underlying NPAT up 20.7% to $279 million despite ongoing industry cost pressure...

The WAM Capital Ltd (ASX: WAM) share price is in focus today after the company reported half-year profit of $24.1 million, an 83.9% decrease from the prior period, and declared an interim dividend of 7.75 cents per share, partially franked...

The Coles Group Ltd (ASX: COL) share price is in focus today after the supermarket giant reported a 2.5% rise in group sales revenue to $23.6 billion and a strong 12.5% lift in net profit (excluding significant items), with continued moment...

The Block (ASX: XYZ) share price is in focus today after the company released its results for the fourth quarter and full year ended 31 December 2025, reporting gross profit growth of 24% over the quarter and a significant 33% rise in Cash...

The PEXA Group Ltd (ASX: PXA) share price is in focus today after the company reported first-half FY26 revenue of $215.3 million, up 10% year-on-year, and Group NPAT of $15.4 million, turning around a prior loss. What did PEXA Group report?...

The Summerset Group Holdings Ltd (ASX: SNZ) share price is in focus after the company delivered a record underlying profit of NZ$234.2 million for the 2025 full year, up 13% on FY24, while total revenue climbed 13% to NZ$361.8 million. What...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is pushing higher today after the company released a fresh update to the market. At the time of writing, the Neuren share price is up 6.37% to $13.52. Let's take a closer look at w...

The Capricorn Metals Ltd (ASX: CCM) share price is in focus today after the company posted record first-half results, including a maiden 5 cents per share fully franked interim dividend. What did Capricorn Metals report? Sales revenue up 6...

The Worley Ltd (ASX: WOR) share price is in focus today as the company reported half-year 2026 results, highlighting 5.4% revenue growth to $6.31 billion and a steady underlying EBITA at $377 million, supported by strong project bookings an...